ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,307Medicare Part D Prescriptions Filled, Including Refills

Rank: 378 out of 4623

$480K Total Retail Price of All Prescriptions

Rank: 808 out of 4623

566 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
31% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

19% of this provider’s 566 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

3% of this provider’s 9,566 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
AMLODIPINE BESYLATE 665 550 1 5
SIMVASTATIN 486 436 2 2
CARVEDILOL 471 418 3 25
LISINOPRIL 458 392 4 4
LISINOPRIL-HYDROCHLOROTHIAZIDE 421 322 5 19
HYDROCODONE-ACETAMINOPHEN 386 255 S3 6 3
METFORMIN HCL 380 335 7 6
ATORVASTATIN CALCIUM 347 301 8 12
PRAVASTATIN SODIUM 274 249 9 11
MELOXICAM 267 247 10 27
HYDROCHLOROTHIAZIDE 247 221 11 10
LOSARTAN POTASSIUM 199 186 12 21
LEVOTHYROXINE SODIUM 194 150 13 1
OMEPRAZOLE 194 170 13 7
FUROSEMIDE 189 180 15 8
GLIMEPIRIDE 182 162 16 38
ALENDRONATE SODIUM 144 141 17 22
POTASSIUM CHLORIDE 141 129 18 14
TAMSULOSIN HCL 136 125 19 29
DOXAZOSIN MESYLATE 126 126 20 98
WARFARIN SODIUM 122 104 21 24
CLONIDINE HCL 117 104 22 40
DONEPEZIL HCL 109 109 23 30
RANITIDINE HCL 106 102 24 47
LOSARTAN-HYDROCHLOROTHIAZIDE 100 89 25 46
METOPROLOL TARTRATE 94 74 26 9
ALLOPURINOL 89 84 27 37
FINASTERIDE 88 88 28 109
CRESTOR 88 70 28 20
ZOLPIDEM TARTRATE 87 50 30 18
FENOFIBRATE 83 62 31 54
FELODIPINE ER 83 77 31 174
NEXIUM 83 57 31 17
FLUTICASONE PROPIONATE 81 67 34 32
DILTIAZEM ER 81 64 34 179
FLUOXETINE HCL 79 65 36 61
CITALOPRAM HBR 77 66 37 23
PREDNISONE 77 64 37 50
NAPROXEN 76 70 39 63
LABETALOL HCL 75 51 40 226
CLOPIDOGREL 72 71 41 31
CYCLOBENZAPRINE HCL 72 53 R 41 53
GABAPENTIN 72 54 41 16
SPIRONOLACTONE 69 66 44 77
OXYBUTYNIN CHLORIDE 61 57 45 120
GUANFACINE HCL 58 56 R 46 291
AMOXICILLIN 55 43 47 95
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 9, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.